Jpmorgan Chase & CO Hille Vax, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Hille Vax, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 48,016 shares of HLVX stock, worth $98,912. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,016
Previous 207,151
76.82%
Holding current value
$98,912
Previous $422,000
83.65%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding HLVX
# of Institutions
81Shares Held
34.9MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$21.9 Million0.97% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$10.1 Million0.46% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$4.31 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$4.03 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.88 Million0.07% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $68.9M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.